This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emisphere Technologies, Inc.
Drug Names(s): Oral Recombinant Human Growth Hormone
Description: Human Growth Hormone (hGH) is a protein hormone secreted from the anterior pituitary gland that stimulates tissue growth and is responsible for linear, skeletal, organ, and cell growth. In addition, hGH has salutary effects on metabolism of proteins, lipids, carbohydrates, and minerals and stimulates the synthesis of chondroitin sulfate and collagen.
Emisphere and Eli Lilly
From 1998 through August 2003, Emisphere developed oral rhGH in collaboration with Lilly. As of August 2003, Lilly returned to Emisphere all rights to the oral rhGH program pursuant to the terms of their license agreement.
Emisphere and Novartis
In September 2004, Emisphere entered into a licensing agreement with Novartis AG to develop an oral formulation of recombinant human growth hormone (rhGH). The companies formed the agreement following successful completion of pre-clinical feasibility studies for rhGH with Emisphere's eligen technology.
Under the terms of the agreement, Emisphere will work with Novartis to initiate clinical trials using its eligen technology. Novartis will fully fund the program including clinical studies. Emisphere will receive up to $34 million during the course of product development, and a royalty increasing to double-digit rates based upon sales. During the first year, Emisphere could receive up to $6...See full deal structure in Biomedtracker
Oral rHGH News
Additional information available to subscribers only: